Senores Pharma Q1FY27 transcript: 36% revenue growth, 87% EBITDA jump; FY27 PAT guidance 50-60%
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Q1FY27 revenue INR180cr, up 36% YoY, driven by 42% regulated markets growth. EBITDA INR54cr, up 87% YoY with margin up 810bps to about 30%. PAT INR31cr, up 56% YoY. Guides FY27 revenue growth 30-40% and PAT growth 50-60%. Targets INR2,500-3,000cr revenue in 3-4 years. ANDA portfolio doubled to 58 approved, 23 commercialized, 35 more to launch in 18-20 months. Emerging markets cash flow positive. Apnar facility at 80-90% capacity. Zoraya and Amerisyn US arms to begin Sept-Oct 2026.
Strong Q1 beat with margin expansion, doubling ANDA portfolio, and clear multiyear revenue target support positive outlook for shareholders.